低便弹性酶-1:在功能性消化不良患者中不可忽视的因素
Jiao Liu1, Tian He1, Linglong Ji1
1Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, No. 37, Guo Xue Alley, Wu Hou Distinct, Chengdu, 610041, Sichuan, China.
Digestive diseases and sciences
|October 29, 2025
概括
近20%的功能性消化不良 (FD) 患者表现出低便弹性酶-1 (FE-1),表明胰腺外分泌功能不充分. 男性性别和焦虑是危险因素,表明酶疗法可能有助于一些FD患者.
科学领域:
- 胃肠病学 胃肠病学
- 消化系统健康 消化系统健康
- 微生物组研究 微生物组研究
背景情况:
- 功能性消化不良 (FD) 是一种常见的胃肠道疾病.
- 消化酶缺乏可能导致FD,但与胰腺外分缺陷 (PEI) 的联系尚不清楚.
- 便弹性酶-1 (FE-1) 是PEI的一个关键指标.
研究的目的:
- 为了确定低FE-1水平在FD患者的患病率.
- 为了确定与FD中低FE-1水平相关的风险因素.
- 探索FE-1水平,临床特征和FD的肠道微生物群之间的关系.
主要方法:
- 76名FD患者的横截面研究.
- 使用ELISA测量FE-1水平;低FE-1定义为<200μg/g便.
- 分析了临床数据,焦虑评分,生活质量和肠道微生物群.
主要成果:
- 在FD患者中,低FE-1 (FE-L) 的患病率为19.7%.
- FE-L组的症状和焦虑得分较高,生活质量较差.
- 男性性别和焦虑是低FE-1的独立风险因素. 在FE-L组中,Prevotella富含;Bacteroides和Bifidobacterium的数量减少.
结论:
- 一大部分FD患者表现出FE-1缺陷.
- 焦虑和男性性别与FD中的胰腺酶分泌量减少有关.
- 胰腺酶补充可能有利于FE-1不足的FD患者.
相关概念视频
Ultrasound II: Endoscopic Ultrasound and FibroScan
538
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
538
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
1.1K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.1K
Drugs for Treatment of Diarrhea-Predominant IBS
618
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
618
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
631
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
631
Peptic Ulcer Disease I: Introduction
734
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
734
Drugs for Treatment of Constipation-Predominant IBS
698
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
698


